NRIX · Nurix Therapeutics, Inc.

Current Thesis

Nurix Therapeutics' Roche-backed bexobrutideg thesis is that clinical progress can renew the rally; a weekly close above the $27.79 reference high would confirm the price leg, while a weekly close below $24 would invalidate it. The September 18, 2026 adjusted close was $25.44, leaving that outcome unresolved.

The September conference window has elapsed. CLL Society's September 18 article discusses results presented at the European Hematology Association (EHA) meeting earlier in 2026; its publication date does not establish a new September dataset. Nurix's release archive, checked September 20, still ends with its September 1 investor-conference announcement. The inference is that the narrative is maturing — the August 4 Phase 3 enrollment announcement remains the latest listed clinical milestone, while September brought additional coverage of existing evidence. CLL Society; Nurix release archive.

Bullish and bearish views on Nurix Therapeutics, Inc.

The model's bull view on Nurix Therapeutics, Inc. (NRIX), in brief: Roche anchors the development case. The July 21, 2026 collaboration-clearance announcement established the partnership behind bexobrutideg. The previously disclosed terms include $700 million upfront and Roche funding 60% of clinical development costs; these support the… The bear view: The anticipated September catalyst expired. Both cases follow in full.

Bull Case

• Roche anchors the development case. The July 21, 2026 collaboration-clearance announcement established the partnership behind bexobrutideg. The previously disclosed terms include $700 million upfront and Roche funding 60% of clinical development costs; these support the development program without establishing clinical success. Roche collaboration announcement, June 8.
• The registrational program has advanced. Nurix announced the first patient enrolled in Phase 3 DAYBreak CLL-306 on August 4, 2026. That is a concrete execution milestone for the chronic lymphocytic leukemia (CLL) program, although enrollment does not establish the trial's outcome. Nurix release archive.
• Clinical activity predates the partnership. Nurix's October 9, 2025 update reported an 80.9% objective response rate among 47 response-evaluable CLL patients at the Society of Hematologic Oncology (SOHO) meeting. That small, early-stage sample supports further investigation; it cannot establish comparative superiority or registration success. Nurix quarterly update.

Bear Case

• The anticipated September catalyst expired. SOHO ran September 9–12, 2026. No new SOHO bexobrutideg dataset was verified in the company releases reviewed through September 20, so the earlier near-term clinical-catalyst premise remains unsupported. The September 18 CLL Society article explicitly attributes its material to EHA. SOHO calendar; CLL Society.
• Price has not confirmed renewal. The September 18, 2026 adjusted close of $25.44 was 8.5% below the supplied $27.79 reference high, despite a three-month price increase of 36.4%. These observations show an unresolved pullback; they do not identify who is transacting.
• Analyst coverage is not unanimous. The earlier $31–40 target range was incomplete: the dated analyst table includes Wells Fargo's $25 target and Jefferies' $45 target, both dated June 8, 2026. These are third-party valuation opinions, not evidence of incremental demand after September's conferences. Analyst action history.

Setup & Price Structure

The September 18, 2026 price series records a 14-day relative strength index (RSI) of 42.8 alongside the $25.44 close. That snapshot does not establish accumulation, distribution or a rising moving average. Volume, moving-average levels and a current short-interest series are missing, so crowding cannot be quantified.

The $24 weekly-close threshold remains the research boundary published September 6; the available snapshot does not independently establish the precise edges of the July and August gaps. The $27.79 reference high supplies an observable confirmation threshold. The forecast remains low-conviction because the September 18 close has not reclaimed that high and no new company-dated clinical catalyst was verified.

Catalyst Calendar (next 30 days)

• ~2026-10-08, estimated quarterly update. Fiscal third-quarter results remain an unconfirmed calendar estimate within September 20–October 20, 2026. Nurix reported the comparable prior-year quarter on October 9, 2025; its current results page does not yet list the 2026 third-quarter release. The relevant disclosures are Roche-related cash receipts, development spending and trial progress. The estimate is not a confirmed clinical readout date. Financial results; Prior-year release.

What Would Change Our Mind

Loss of the remaining post-announcement structure would end the price thesis: a weekly close below $24 is the observable break. Conversely, a weekly close above the September 18 reference high of $27.79 before that break would satisfy the published price case. A newly announced dataset would change the catalyst assessment, but the September 18 recap of EHA results does not meet that condition.

Correlation Notes

This remains a single-name clinical setup. The July 21 Roche collaboration clearance and August 4 trial-enrollment announcement are identifiable company events; the available September 18 price snapshot contains no matched sector-return series. No measured correlation with biotechnology equities, Roche or competing degrader developers can be asserted from this evidence.